StockNews.AISignal intelligence
Glaukos Corporation · NYSE · Healthcare
Browse public GKOS signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Glaukos Corp (NYSE: GKOS) announced its fourth-quarter earnings, which were mixed and could impact investor sentiment. Uncertainty surrounding future growth and performance may pressure the stock in the short term as investors reassess their positions based on these results.
View signal analysisFDA approved Glaukos Corp's new eye therapy for vision-related condition. The treatment offers a less painful and more convenient option for patients.
View signal analysisGKOS received FDA Day 74 notification; NDA for Epioxa accepted for review. Phase 3 trials hit primary endpoints; data shows favorable safety and efficacy. Epioxa offers non-invasive keratoconing treatment; uses novel drug formulation. FDA review goal set to Oct 20, 2025; stock up 25% in premarket.
View signal analysisStifel raised GKOS price target from $153 to $175. Analyst Thomas Stephan maintained a Buy rating for Glaukos Corporation. Glaukos shares closed at $149.51 on the last trading session.
View signal analysisMorgan Stanley downgraded Glaukos Corporation to Underweight due to valuation risks. Analyst sees long-term potential in iDose, but current valuation limits upside. Company's pipeline projects are promising but remain years away from fruition. Overall MedTech outlook is bullish despite some company-specific challenges. Morgan Stanley upgraded other MedTech stocks, highlighting strong demand and growth potential.
View signal analysisGKOS reported $96.7M in Q3 sales, 24% growth. Adjusted EPS loss narrowed to $(0.28), beating estimates. Gross margins improved slightly, indicating operational stability. Glaucoma products sales rose 30%, strong market performance. Guidance for 2024 sales raised, now at $377-$379M.
View signal analysis